Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include a) the Ras pathway program with a small molecule clinical candidate with selective anti-tumor activity, b) the colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.
Prolexys' ability to identify and validate novel therapeutic targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. Prolexys has developed two key technologies, a high throughput yeast 2 hybrid system called HyNet, and a mass spectrometry-based protein science technology called HySpec, that complement one another and provide a powerful approach for identifying novel molecular targets relevant to the treatment of human disease. In addition, Prolexys has developed HyScreen, to validate the therapeutic utility of these novel targets as well as in house high-throughput screening, in vivo pharmacology, medicinal chemistry, and drug development capabilities.
Prolexys was formed in 2001 with investments from Myriad Genetics, Inc., Hitachi Ltd., Friedli Corporate Finance, A.G., and Oracle Corporation. The company is privately held and located in Salt Lake City, Utah.
